logo-loader
viewScancell Holdings PLC

Scancell exploring new frontiers in cancer research

Snapshot

Here we take a closer look at Scancell, which is at the vanguard of immuno-oncology

lab worker

Quick facts: Scancell Holdings PLC

Price: 5.55 GBX

LSE:SCLP
Market: LSE
Market Cap: £25.83 m
Follow
  • Developing innovative cancer immunotherapies
  • Four lead products in development
  • Started work on a coronavirus vaccine

What the company does

AIM-listed Scancell Holdings PLC (LON:SCLP) is at the vanguard of advances in the emerging field of immuno-oncology and is working on two technologies that are showing promise – they are the ImmunoBody and Moditope platforms.

The former has spawned the company’s most advanced cancer drugs, SCIB-1 and SCIB-2. It is also developing MODI-1 and MODI-2 from the Moditope platform.

Scancell Holdings PLC (LON:SCLP)  lead drug, SCIB-1, developed from its ImmunoBody technology, has recently entered a phase II clinical trial in the UK.

The study will initially assess the safety and efficacy of the treatment in 25 people with a metastatic form of skin cancer, melanoma. SCIB-1 will be used in harness with Merck’s checkpoint inhibitor Keytruda.

A £3.9mln injection from the life sciences fund Vulpes will effectively bankroll the latest R&D.

Inflexion points

The company expects to generate meaningful clinical data in the next two years from all four of its drug candidates (see below).

 

CRUK is planning a clinical trial to investigate the safety and efficacy of the SCIB2-nanoparticle complex in patients with solid tumours.

And a planned phase I/II clinical study is of MODI-1 is expected to begin in the second half.

Meanwhile, the company is already signing collaboration deals for its AvidiMab technology, having currently inked a deal with three partners, most recently a US antibody company in January.

The US firm will conduct preclinical studies to evaluate the potential for the anti-TaG mAbs developed by AvidiMab to treat cancer. A similar deal was secured with a Chinese biotech in December.

Coronavirus 

In April, Scancell announced it had begun a research programme to develop a vaccine for the coronavirus.

The project, to be led by the company’s chief scientific officer Lindy Durrant, will aim to utilise the company’s clinical expertise in cancer to produce a cost-effective and scalable vaccine to induce both durable T cell responses and virus neutralising antibodies against coronavirus

Initial research is now underway, with the company anticipating a phase 1 clinical trial in the first quarter of 2021.

The firm is also “actively seeking” development partners and additional partners to support rapid development of the vaccine.

What the boss says: Cliff Holloway, chief executive 

 

 

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Scancell Holdings PLC named herein, including the promotion by the Company of Scancell Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Canafarma's DTC marketing strategy 'an important driver' for the company -...

Proactive Research analyst Ed Stacey says CanaFarma Hemp Products Corp (CSE:CNFA, FRA:4K9) has a vertically integrated ‘farm-to-table’ strategy encompassing cultivation, extraction/process, manufacture of branded consumer products and sales & marketing. Stacey says the firm is...

4 weeks, 1 day ago

3 min read